StreetAlpha
13F holdings · Q3 2026

Frazier Life Sciences Management

Palo Alto, CA · files as Frazier Life Sciences Management, L.P.
Know the moment Frazier Life Sciences Management filesYou follow Frazier Life Sciences Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1892134

Frazier Life Sciences Management reported 44 stocks worth $4B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are MIRM (16.3%), NAMS (11.5%) and ERAS (10.7%). Compared with Q2 2026, the fund opened new positions in ATTO, BRVE and ASND, added to NAMS, ERAS and MAZE, trimmed TRVI, KRYS and IRON and sold out of BBIO, CYTK and ASND.

Latest filing: what Frazier Life Sciences Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
7 new10 added5 trimmed4 sold outBought about $531M · sold about $419M
New 7
See all 7 →
Added 10
See all 10 →
Trimmed 5
Sold out 4

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$4B−12.2% vs last quarter
Stocks held447 new · 4 sold out
Top 5 weight54.6%fairly concentrated
Turnover24%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
MIRM
Mirum Pharmaceuticals Inc
$656M16.3%7.7MNo change8 of 8
2
NAMS
Newamsterdam Pharma Company
$462M11.5%19M+900K (+5%)8 of 8
3
ERAS
Erasca Inc
$432M10.7%29.5M+4.5M (+18%)8 of 8
4
MBX
Mbx Biosciences Inc
$390M9.7%6.7MNo change8 of 8
5
ARQT
Arcutis Biotherapeutics Inc
$261M6.5%9.9MNo change8 of 8
6
MAZE
Maze Therapeutics Inc
$144M3.6%5.3M+250K (+5%)7 of 8
7
TRVI
Trevi Therapeutics Inc
$137M3.4%9.5M−400K (−4%)8 of 8
8
KRYS
Krystal Biotech Inc
$130M3.2%391K−90K (−19%)8 of 8
9
PVLA
Palvella Therapeutics Inc NE
$122M3.0%882KNo change8 of 8
10
ATTO
Attovia Therapeutics Inc
$121M3.0%7MNew position1 of 8
🔒 34 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
BBIO
Bridgebio Pharma Inc
$115M1.5M
CYTK
Cytokinetics Inc
$98.8M1.2M
ASND
Ascendis Pharma A/s
$60.1M225K
ALKS
Alkermes PLC
$36.7M701K

Reported value

last 8 quarters
$2.4BQ4 '24
$2.2BQ1 '25
$2.5BQ2 '25
$3.3BQ3 '25
$3.7BQ4 '25
$3.9BQ1 '26
$4.6BQ2 '26
$4BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Frazier Life Sciences Management 13F FAQ

What does Frazier Life Sciences Management own?

Frazier Life Sciences Management reported 44 stocks worth $4B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are MIRM (16.3%), NAMS (11.5%) and ERAS (10.7%). The table above lists every position in the filing (the top 10 without an account).

What did Frazier Life Sciences Management buy and sell in Q3 2026?

Compared with Q2 2026: 7 new positions, 10 added to, 5 trimmed and 4 sold out. New positions include ATTO, BRVE and ASND. It sold all of BBIO, CYTK and ASND.

When will Frazier Life Sciences Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Frazier Life Sciences Management's portfolio worth?

The Q3 2026 filing reports $4B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.